Health Sector News: Key Developments and Legal Battles

Democratic-led states challenge Trump's gutting of health agencies. Tyson Foods eliminates synthetic dyes. Trump to sign domestic drug manufacturing order. Zimmer Biomet lowers profit forecast amid tariffs. Medicaid work requirements reconsidered. FDA to review Capricor's therapy. Rite Aid files for bankruptcy. BioNTech appoints new CFO.

A coalition of Democratic-led states is suing to prevent the Trump administration from significantly reducing the workforce and operations of the U.S. Department of Health and Human Services. Attorneys general argue that these cuts will compromise the agency's effectiveness, violating constitutional norms.

In the food sector, Tyson Foods is taking proactive steps by removing petroleum-based synthetic dyes from its products. The company aims to complete this transition by the end of May, ensuring that most of its retail-branded items, including popular chicken nuggets, are free from such additives.

President Trump plans to encourage domestic drug manufacturing by streamlining pharmaceutical regulations. An executive order will instruct the FDA to expedite approval processes for local manufacturing, while also increasing fees for foreign site inspections. This move aims to bolster U.S. pharma production and reduce dependency on international sources.

(With inputs from agencies.)